Approximately, preferentially expressed antigen in melanoma (PRAME), a tumor-associated antigen is expressed in around 80% of medulloblastomas [58], and it also exhibited promising results when engineered into CAR T-cell targets in orthotopic medulloblastoma models [59]. This evidence concerns the gene PRAME and melanoma.